Tekmira Merges With OnCore In Hopes Of Building Hepatitis B Powerhouse
This article was originally published in The Pink Sheet Daily
The two small biotechs are coming together to create a hepatitis B-focused company that management hopes will mirror the success seen with hepatitis C companies.
You may also be interested in...
Moderna Again Faces Claims It Excluded Others’ Work In Developing COVID-19 Vaccine
Arbutus Biopharma alleges Moderna refused to license patents covering its lipid nanoparticle delivery platform in developing Spikevax. Moderna says it created its own proprietary LNP delivery technology.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.